新股消息 | 普莱医药递表港交所 核心产品PL-5已提交新药上市申请

Company Overview - Plai Pharmaceuticals (Jiangsu) Co., Ltd. is a leading innovative antimicrobial peptide (AMP) therapeutic drug company established in April 2009, focusing on four core therapeutic areas: anti-infection, metabolic diseases, tumors, and autoimmune diseases [2] - The company has nine candidate drugs, including one core product (PL-5) and two major products (PL-3301 and PL-18) [2] - PL-5 is the first globally submitted new drug application (NDA) for a class of drugs known as cationic peptides, representing a novel mechanism of action to combat antibiotic resistance [2][3] Product Pipeline - PL-5 is entering the regulatory submission phase in China in 2024 and is undergoing Phase II clinical trials in the United States [3] - PL-3301 is a potential first-in-class temperature-sensitive peptide gel for treating oropharyngeal candidiasis, while PL-18 targets vulvovaginal candidiasis and may also treat various gynecological infections [3] - The company is expanding its pipeline to include treatments for metabolic diseases, tumors, and autoimmune diseases, with several assets in preclinical stages [3] Financial Performance - For the fiscal year 2024, the company reported revenues of approximately RMB 5.194 million, with a gross profit of about RMB 2.174 million [6][7] - The company recorded a net loss of approximately RMB 158.337 million for the fiscal year 2024, primarily due to research and development expenses and administrative costs [8] Industry Overview - The global peptide drug market is projected to grow from USD 62.8 billion in 2020 to USD 109.6 billion by 2024, with a compound annual growth rate (CAGR) of 5.8% expected from 2030 to 2035, reaching USD 288.5 billion [9] - The global anti-infection drug market is expected to reach USD 137.9 billion in 2024, with a slight decline anticipated by 2030, followed by a recovery to USD 145.7 billion by 2035 [11] - The peptide-based anti-infection drug market is projected to grow from USD 1.9 billion in 2024 to USD 5.7 billion by 2035, with a CAGR of 10.3% from 2024 to 2030 [14]